All In Biotech

Drug Trial Radar · NCT04640168

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-4)

Last checked: Nov 19, 2026Latest source record: Jun 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,010 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,010

Actual

Start

Dec 2, 2020

Primary completion

May 18, 2021

Study completion Jun 18, 2021

Sponsor

Sponsor type
NIH
First posted
Nov 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests, oropharyngeal (OP) swabs, plasma (Day 29), and serum for secondary research as well as clinical outcome data. However, if infection control or other restrictions limit the ability of the subject to return to the clinic, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The primary objective is to evaluate the clinical efficacy of baricitinib + remdesivir versus dexamethasone + remdesivir as assessed by the mechanical ventilation free survival by Day 29.

Conditions

  • COVID-19

Interventions

  • BaricitinibDrug

    Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.

  • DexamethasoneDrug

    Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.

  • PlaceboOther

    Placebo matching oral baricitinib or intravenous dexamethasone.

  • RemdesivirDrug

    Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)Time frame: Day 1 through Day 29
  2. The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by RaceTime frame: Day 1 through Day 29
  3. The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by EthnicityTime frame: Day 1 through Day 29
  4. The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by SexTime frame: Day 1 through Day 29

Locations

72 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham School of Medicine - Infectious Disease

    Birmingham, Alabama

  • UCSF Fresno Center for Medical Education and Research - Clinical Research Center

    Fresno, California

  • University of California San Diego Health - Jacobs Medical Center

    La Jolla, California

  • University of California Los Angeles Medical Center - Westwood Clinic

    Los Angeles, California

  • University of California Irvine Medical Center - Infectious Disease

    Orange, California

  • VA Palo Alto Health Care System - Infectious Diseases

    Palo Alto, California

  • University of California Davis Medical Center - Internal Medicine - Infectious Disease

    Sacramento, California

  • Kaiser Permanente San Diego Medical Center

    San Diego, California

  • Naval Medical Center San Diego - Infectious Disease Clinic

    San Diego, California

  • University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine

    San Francisco, California

  • Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases

    Stanford, California

  • Cedars Sinai Medical Center

    West Hollywood, California

  • VA Eastern Colorado Health Care System

    Aurora, Colorado

  • Denver Health Division of Hospital Medicine - Main Campus

    Denver, Colorado

  • Georgetown University Medical Center - Division of Infectious Diseases

    Washington D.C., District of Columbia

  • University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine

    Gainesville, Florida

  • University of Florida Health - Jacksonville - Department of Emergency Medicine

    Jacksonville, Florida

  • University of Miami Miller School of Medicine - Infectious Diseases

    Miami, Florida

  • Emory Vaccine Center - The Hope Clinic

    Decatur, Georgia

  • Atlanta VA Medical Center - Infectious Diseases Clinic

    Decatur, Georgia

  • Tripler Army Medical Center

    Honolulu, Hawaii

  • Northwestern Hospital - Infectious Disease

    Chicago, Illinois

  • University of Illinois at Chicago College of Medicine - Division of Infectious Diseases

    Chicago, Illinois

  • University of Iowa Hospitals & Clinics - Department of Internal Medicine

    Iowa City, Iowa

  • Tulane University - Section of Pulmonary Diseases, Critical Care, and Environmental Medicine

    New Orleans, Louisiana

  • University of Maryland School of Medicine - Center for Vaccine Development - Baltimore

    Baltimore, Maryland

  • Johns Hopkins Hospital - Medicine - Infectious Diseases

    Baltimore, Maryland

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section

    Bethesda, Maryland

  • Massachusetts General Hospital - Infectious Diseases

    Boston, Massachusetts

  • University of Massachusetts Medical School - Infectious Diseases and Immunology

    Worcester, Massachusetts

  • University of Michigan - Infectious Disease Clinic at Taubman Center

    Ann Arbor, Michigan

  • University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine

    Minneapolis, Minnesota

  • Saint Louis University - Center for Vaccine Development

    St Louis, Missouri

  • University of Nebraska Medical Center - Infectious Diseases

    Omaha, Nebraska

  • CHI Health Creighton University Medical Center - Bergan Mercy - Pulmonary Medicine

    Omaha, Nebraska

  • Atlantic Health System - Morristown Medical Center

    Morristown, New Jersey

  • University of New Mexico Clinical and Translational Science Center

    Albuquerque, New Mexico

  • New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology

    New York, New York

  • University of Rochester Medical Center - Vaccine Research Unit

    Rochester, New York

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.